Gregory Z. Ferl, Ph.D.
Affiliations: | 2005 | University of California, Los Angeles, Los Angeles, CA |
Area:
Biomedical Engineering, Cell BiologyGoogle:
"Gregory Ferl"Parents
Sign in to add mentor| Owen N. Witte | grad student | 2005 | UCLA | |
| (Computational systems biology of the B cell, its neoplastic transformation and clinical treatment.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Nazarova L, Rafidi H, Mandikian D, et al. (2020) Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-Length Antibodies. Molecular Cancer Therapeutics |
| Boswell CA, Yadav DB, Mundo EE, et al. (2019) Biodistribution and efficacy of an anti-TENB2 antibody-drug conjugate in a patient-derived model of prostate cancer. Oncotarget. 10: 6234-6244 |
| Riegler J, Gill H, Ogasawara A, et al. (2019) VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models. Neoplasia (New York, N.Y.). 21: 1036-1050 |
| Mandikian D, Rafidi H, Adhikari P, et al. (2018) Site-specific conjugation allows modulation of click reaction stoichiometry for pretargeted SPECT imaging. Mabs |
| Ferl GZ, Reyes A, Sun LL, et al. (2018) A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clinical and Translational Science |
| Hsu YH, Huang Z, Ferl GZ, et al. (2015) GPU-accelerated compartmental modeling analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab. Plos One. 10: e0118421 |
| Ferl GZ, O'Connor JP, Parker GJ, et al. (2015) Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab. Journal of Magnetic Resonance Imaging : Jmri. 41: 132-41 |
| Hsu YH, Ferl GZ, Ng CM. (2013) GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab. Magnetic Resonance Imaging. 31: 618-23 |
| Ferl GZ, Port RE. (2012) Quantification of antiangiogenic and antivascular drug activity by kinetic analysis of DCE-MRI data Clinical Pharmacology and Therapeutics. 92: 118-124 |
| Boswell CA, Ferl GZ, Mundo EE, et al. (2011) Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. Plos One. 6: e17874 |